Navigation Links
International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment
Date:8/10/2011

IRVINE, California and AMSTERDAM, August 10, 2011 /PRNewswire/ --

Agendia, a commercial-stage molecular cancer diagnostics company, today announced that the 12th St. Gallen International Breast Cancer Conference (2011) Expert Panel's recommendations highlight the value of molecular subtyping - classifying patients by the particular biological subtype of their tumor - in guiding treatment decisions for breast cancer patients. According to the panel, "it is no longer tenable to consider breast cancer as a single disease" and clinicians "should consider cases within the various distinct subtypes in order to properly assess the relevant evidence and arrive at appropriate therapeutic advice." The panel's updated guidelines, which are released on a semiannual basis, appear in the August 2011 issue of Annals of Oncology in an article titled "Expert Consensus on the Primary Therapy of Early Breast Cancer 2011" by Goldhirsch, et al (Annals of Oncology 22: 1736-1747, 2011).

The panel's recommendations support the clinical value of Agendia's BluePrint assay, which, in combination with the company's FDA-cleared MammaPrint® recurrence test, can accurately classify all patients as Basal, Luminal-A, Luminal-B, or ERBB2 (HER2) and help determine appropriate treatment. Both clinically available, MammaPrint and BluePrint are two components of Agendia's Symphony™ suite of breast cancer treatment products, a comprehensive collection of genetic assays that help address complex treatment decisions for any type and stage of breast cancer.

The panel also recognized that MammaPrint provided such accurate prognoses that patients and physicians may decide that chemotherapy is not required. MammaPrint identifies patients' risk of metastasis, placing them into one of just two groups, high risk and low risk. Women in the low risk group are able to be treated effectively and safely without undergoing chemotherapy and its side effects.

"These r
'/>"/>

SOURCE Agendia B.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results
2. Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011
3. Millennium Surgical Provides Services and Support to CURE Internationals Zambian Surgical Program
4. HUYA Bioscience International and Shanghai Jiao Tong University Kings Lab Form Alliance
5. Masimo Introduces Pronto-7™ Internationally and Lifts Voluntary Recall
6. HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010
7. VWR International, LLC to Acquire LabPartner (Shanghai) Co., Ltd.
8. Lightwave Logic Addresses the Bio-Medical Diagnostic Market through an Agreement with FiberLogix International Ltd.
9. FedEx Donates $5 Million and MD-10-30 Aircraft to ORBIS International
10. FDA, International Counterparts Report Progress on Drug Inspection Collaboration
11. Chindex International, Inc. to Report Financial Results for the Second Quarter and First Half of 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- SAM Medical ... Strap for the SAM Junctional Tourniquet.  ... SAM Medical Products announced today that it ... to address a potential issue with a clip ... the Axilla application of the SAM Junctional Tourniquet ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 /PRNewswire/ ... Medina Medical as CEO and member of the Board ... three decades of medical device development and commercialization experience, ... Medical,s field. Mr. Engelson previously served as a Partner ... served as President and CEO of two Foundry start-ups. ...
(Date:8/29/2014)... -- Research and Markets has announced the ... & Pipeline Insight 2014" report to their offering. ... and eradicate the prevalence of cancer have achieved limited ... low specificity, safety and large number of side effects, ... solution. It has been discovered that peptides can be ...
Breaking Medicine Technology:SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2
... Aug. 5, 2011 Varian Medical Systems, Inc. (NYSE: ... former CEO and member of the Board of Directors for ... of management in global medical device businesses, has been appointed ... Varian,s Board of Directors also increased its size from nine ...
... FOREST, Ill., Aug. 5, 2011 Hospira, Inc. (NYSE: ... today announced U.S. Food and Drug Administration (FDA) approval of ... presentations include 200 mg, 1 gm and 2 gm with ... sales of more than $750 million in 2010, led by ...
Cached Medicine Technology:Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection 2Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection 3
(Date:8/30/2014)... 30, 2014 Hundreds of Byetta lawsuits ... to move forward in U.S. courts, Bernstein Liebhard LLP ... on July 31, 2014, Byetta and Bydureon (an extended-release ... liability claims that allege the drugs caused pancreatitis, pancreatic ... of these claims are pending in a multidistrict litigation ...
(Date:8/30/2014)... Springs, CO (PRWEB) August 30, 2014 In ... and increasingly difficult to get. Snoring and sleep apnea (a ... stops) rob people and their bed partners of the rest ... to 45% of the population snores and 20 million people ... only 10% have been diagnosed and treated; and of those ...
(Date:8/30/2014)... 2014 Market Research Report on ... a professional and in-depth market survey on Global ... reviews the basic information of Lab Oven including ... then explores global and China’s top manufacturers of ... value, and market share etc. , The report ...
(Date:8/30/2014)... 30, 2014 The federal judge ... ( http://www.injurybeacon.com/transvaginal-mesh/ ) filed against Boston Scientific Corp. ... cases selected for one of the proceeding’s bellwether ... 18, 2014, U.S. District Judge Joseph R. Goodwin ... with Boston Scientific’s contention that a consolidated trial ...
(Date:8/30/2014)... 30, 2014 In today’s world, a ... difficult to get. Snoring and sleep apnea (a medical ... stops) robs people and their bed partners of the ... to 45% of the population snores and 20 million ... Of these, only 10% have been diagnosed and treated; ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... Spanish . , The " La Mente Bilinge " ... Arts at the University of the Basque Country analyses bilingual processing ... acquires and manages languages and to discover in what way languages ... In order to understand how we become fluent in a language ...
... make healthy choices, study shows , , MONDAY, June 30 (HealthDay News) ... serving of baked or fried food bad for you, or can ... no amount of the artery-clogging artificial fat is good for ... panel found on the side of grocery store products does a ...
... on Outstanding Quality and Compliance -, LEXINGTON, ... that it has received the prestigious Supplier,Performance Award ... The,award recognizes outstanding performance in quality and compliance ... as award winners. IL,was presented with the honor ...
... WEST CONSHOHOCKEN, Pa., June 30 Cadient Group, ... today announced that Stephen Wray, President and CEO ... Young Entrepreneur Of The Year(R) in the,Greater Philadelphia ... program,was designed to recognize outstanding entrepreneurs on a ...
... MUMBAI, India, June 30 Sun Pharmaceutical,Industries Ltd. ... today announced that Alkaloida Chemical Company Exclusive Group,Ltd. ... a tender offer,for all outstanding Ordinary Shares of ... share in cash., On May 18, 2007, ...
... Health Solutions Corp.,("SXC" or the "Company") (NASDAQ: ... and pharmacy benefits management services, announces a five ... benefit management,("PBM") services with The University of Toledo ... for more than 6,000 members of,UT,s employee prescription ...
Cached Medicine News:Health News:Laka: 'Language exists in the brain' 2Health News:Laka: 'Language exists in the brain' 3Health News:Laka: 'Language exists in the brain' 4Health News:Trans Fat Labeling Gets Tricky 2Health News:Trans Fat Labeling Gets Tricky 3Health News:Trans Fat Labeling Gets Tricky 4Health News:Trans Fat Labeling Gets Tricky 5Health News:Instrumentation Laboratory Receives Performance Award from Premier for Second Consecutive Year 2Health News:Cadient Group President and CEO, Stephen Wray, Named 2008 Ernst & Young Entrepreneur Of The Year(R) in Greater Philadelphia Region 2Health News:Cadient Group President and CEO, Stephen Wray, Named 2008 Ernst & Young Entrepreneur Of The Year(R) in Greater Philadelphia Region 3Health News:Sun Pharma Commences All Cash Tender Offer to Purchase Taro Ordinary Shares for USD 7.75 Per Share 2Health News:Sun Pharma Commences All Cash Tender Offer to Purchase Taro Ordinary Shares for USD 7.75 Per Share 3Health News:The University of Toledo selects SXC Health Solutions (informedRx) to provide pharmacy benefit management services 2Health News:The University of Toledo selects SXC Health Solutions (informedRx) to provide pharmacy benefit management services 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... System is a panel mounted system that offers ... needs of the heath care professional using the ... available with a dual action lever that allows ... to an IV pole. Similarly, it features ...
Medicine Products: